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a  b  s  t  r  a  c  t
T-cell  mediated  immune  responses  are  critical  for  acquired  immunity  against  infection  by  the  intracellular
protozoan  parasite  Trypanosoma  cruzi.  Despite  its  importance,  it is  currently  unknown  where  protective  T
cells  are  primed  and  whether  they  need  to  re-circulate  in order  to  exert  their  anti-parasitic  effector  func-
tions.  Here,  we show  that  after  subcutaneous  challenge,  CD11c+-dependent  speciﬁc  CD8+ T-cell  immune
response  to immunodominant  parasite  epitopes  arises  almost  simultaneously  in  the draining  lymph  node
(LN)  and  the  spleen.  However,  until day  10  after  infection,  we  observed  a  clear  upregulation  of activation
markers  only  on  the  surface  of CD11C+PDCA1+ cells  present  in  the  LN  and  not  in  the  spleen.  Therefore,
we  hypothesized  that  CD8+ T  cells  re-circulated  rapidly  from  the LN  to  the  spleen.  We  investigated  this
phenomenon  by  administering  FTY720  to  T.  cruzi-infected  mice  to prevent  egress  of  T  cells  from  the LN  by
interfering  speciﬁcally  with  signalling  through  sphingosine-1-phosphate  receptor-1.  In  T.  cruzi-infected
mice  receiving  FTY720,  CD8  T-cell  immune  responses  were  higher  in  the  draining  LN and signiﬁcantly
reduced  in  their  spleen.  Most  importantly,  FTY720  increased  susceptibility  to infection,  as indicated  by
elevated  parasitemia  and  accelerated  mortality.  Similarly,  administration  of  FTY720  to mice  genetically
vaccinated  with  an  immunodominant  parasite  antigen  signiﬁcantly  reduced  their  protective  immunity,
as  observed  by the parasitemia  and  survival  of  vaccinated  mice.
We concluded  that  re-circulation  of  lymphocytes  mediated  by sphingosine-1-phosphate  receptor-1
greatly  contributes  to acquired  and  vaccine-induced  protective  immunity  against  experimental  infection
 paraswith  a human  protozoan
. Introduction
T  cells are important mediators of the adaptive immune
esponse against infections caused by intracellular microorgan-
sms, including the digenetic intracellular protozoan parasite
rypanosoma cruzi, the causative agent of Chagas disease (American
rypanosomiasis). Genetic deﬁciency or speciﬁc treatments lead-
ng to the depletion of CD4+ or CD8+ T cells critically impairs the
cquired immunity observed during experimental mouse infection
1–4]. Although, the anti-parasitic effect exerted by the T cells is
∗ Corresponding authors at: CTCMol, UNIFESP – Escola Paulista de Medicina, Rua
irassol, 207, São Paulo-SP, 04044-010, Brazil. Tel.: +55 11 5571 1095;
ax: +55 11 5571 1095.
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© 2012 Elsevier Ltd. 
largely mediated by IFN-, other mediators may  also participate in
the efﬁcient elimination of parasites from the host [1–4].
In  inbred mouse strains or humans, MHC  class II-restricted CD4+
T cells recognize multiple antigens from T. cruzi [5–9], whereas
MHC class Ia-restricted CD8+ T cells are primarily speciﬁc for
immunodominant epitopes that are expressed by surface antigens
members of a large family of T. cruzi proteins named trans-sialidases
(TS) [1,4,9–18]. T cells are not only critical for acquired immunity,
but they are also important mediators of protective immunity in
response to vaccination with recombinant proteins, plasmid DNA,
and bacteria- and virus-based vaccine constructs against T. cruzi
[19–25]. Additionally, as in the case of immunity acquired dur-
ing infection, IFN- is a key mediator of protective immunity [25].
Open access under the Elsevier OA license.Despite the important role of T-cell mediated immune responses,
it is currently unknown where protective T cells are primed and
whether they need to re-circulate in order to exert their anti-
parasitic effector functions during acquired immune responses.
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With this aim, we ﬁrst evaluated the kinetics of CD8+ T-cell
ctivation in the LN and spleen following a subcutaneous para-
ite challenge. Although the kinetics of activation in both locations
ere very similar, we detected the presence of clearly activated
D11C+ Plasmacytoid Dendritic Cells 1+ (PDCA-1) cells only in the
N. CD11C+ PDCA-1+ are known for their capacity to secrete large
mounts of type I IFN upon activation. But most important for our
urposes, very recently, they have been implicated in the priming
f CD8+ T cells [26]. Based on that, we hypothesized that CD8+ T cells
ere activated at the LNs and re-circulated rapidly to the spleen.
To  evaluate this possibility, we administered an immuno-
uppressive drug, FTY720, to interfere with T-cell signalling via
he sphingosine-1-phosphate receptor-1 (S1P1). This receptor is
xpressed on T cells that respond to S1P1 by emigrating out of the
hymus, LN, and bone marrow [27–29]. Following T-cell activation,
1P1 is transiently downmodulated, resulting in prolonged resi-
ence of T cells within lymphoid tissues and improved priming
fﬁcacy. FTY720 interferers with this process, since upon applica-
ion, it becomes rapidly phosphorylated to FTY720-P, thus behaving
s a strong S1P1 agonist. This results in sustained inhibition of
1P1 signalling, effectively trapping naive and recently activated
 cells within the secondary lymphoid. Although FTY720 allows T-
ell priming, it efﬁciently blocks migration of activated T cells from
he LNs to the peripheral tissues and thereby precludes peripheral
-cell responses [27–29].
Essentially,  we observed that administration of FTY720 after
hallenge with T. cruzi in mice that normally survive acute infection
C57Bl/6) or susceptible vaccinated A/Sn mice led to a signiﬁ-
ant increase in the susceptibility to infection, as indicated by
levated parasitemia and accelerated mortality. Together, these
esults corroborate the hypothesis that re-circulation of T lympho-
ytes mediated by S1P1 plays an important role during acquired or
accine-induced protective immune responses to T. cruzi infection.
. Methods
.1. Ethics statement
This  study was carried out in strict accordance with the rec-
mmendations in the Guide for the Care and Use of Laboratory
nimals of the Brazilian National Council of Animal Experimen-
ation (http://www.cobea.org.br/).  The protocol was  approved by
he Committee on the Ethics of Animal Experiments of the Institu-
ional Animal Care and Use Committee at the Federal University of
ao Paulo (Id # CEP 0426/09).
.2.  Mice and parasites
Female  8-week-old mice (C57BL/6 and A/Sn) were purchased
rom CEDEME (Federal University of São Paulo). Transgenic mice
xpressing the diphtheria toxin receptor (DTR) under control of
he CD11c promoter (CD11c-DTR) on a C57BL/6 background were
erived as described and were maintained in our colony as het-
rozygotes [30]. Blood-derived trypomastigotes of the Y strain of
. cruzi were obtained from A/Sn mice infected 7–8 days earlier.
ach C57BL/6 or A/Sn mouse was challenged sub-cutaneously (s.c.)
t the base of the tail with a ﬁnal dose containing 104–105 or 150
arasites, respectively, in a ﬁnal volume of 0.1 mL.  Parasite devel-
pment was monitored by counting the number of blood-derived
rypomastigotes in 5 L of fresh blood collected from the tail vein
10]..3. Administration of DT or FTY720
Wild type (WT) and CD11c-DTR mice were treated i.p. with 2
oses of 50 ng diphtheria toxin from Corynebacterium diphteriaee 30 (2012) 2882– 2891 2883
(DT,  Sigma), 48 h before and on the same day of challenge. In addi-
tion, infected WT mice were treated every other day, beginning on
the same day of infection, with doses of 20 g FTY720 (Cayman
Chemical, Ann Arbor, MI)  per mouse (1 mg/kg) in a ﬁnal volume of
0.2 mL.  The control mice were injected with the diluent only.
2.4. Peptides
Peptides were purchased from Genscript (Piscataway, NJ). Purity
was as follows: VNHRFTLV, 97.2% and TsKb-20 (ANYKFTLV), 99.7%.
2.5. Recombinant plasmids and adenoviruses
Plasmid pIgSPCl.9 and the human replication-defective aden-
ovirus type 5 containing the asp-2 gene were described previously
[22,24,25,31]. Heterologous prime-boost immunization involved
priming i.m. with 100 g of plasmid DNA followed by a dose of viral
suspension containing 2 ×108 plaque-forming units (pfu) of aden-
ovirus 21 days later in the same locations. Immunological assays or
challenges were performed 14 days after viral inoculation (boost).
2.6.  Phenotypic cell analyses by ﬂow cytometry
The panel of conjugated antibodies used for FACS analyses were
CD11c-FITC (clone HL3), CD19-PECy7 (clone 1D3), CD8-PerCP
(clone 53-6.7), CD86-APC (clone GL1), CD80-APC (clone 16-10A1),
CD40-APC (clone 3/23) all from BD; PDCA-1-PE (clone JF05-1C2.4.1)
from Miltenyi Biotec. Single-cell suspensions from Inguinal lymph
nodes or spleen were stained for surface markers on ice for 20 min,
and then washed twice in buffer containing PBS, 0.5% BSA, and
2 mM EDTA ﬁxed in 4% PBS-paraformaldehyde solution for 10 min.
At least 300,000 events were acquired on a BD FACSCanto II ﬂow
cytometer and then analyzed with FlowJo (Tree Star, Ashland, OR).
2.7. Sorting of cells by ﬂow cytometry
PDCA-1+ cells were isolated from LN collected from C57BL/6
mice infected 5 days earlier s.c. with 104 T. cruzi parasites. As con-
trols, we  used PDCA-1+ cells isolated from LN of naïve C57BL/6 mice
(n = 15). Inguinal lymph nodes were removed, collagenase-treated,
and the single cell suspension was stained with the following anti-
bodies: CD3 Paciﬁc Blue (500A2), IAb FITC (25-9-17), CD11c APCCy7
(HL3) all from BD, and PDCA-1 PE (JF05-1C2.4.1) from Miltenyi
Biotec. CD3− IAb+ CD11c+ PDCA-1+ cells were then sorted in a BD
FACSAria III cell sorter.
CD8+ cells were obtained from C57BL/6 mice (n = 2) s.c. infected
with 104 T. cruzi parasites. Spleens were removed 15 days after
infection. Following red blood cell lysis, a single cell suspension
was stained with CD8 PE (53-6.7) from BD and positive cells were
subjected to sorting in a BD FACSAria III cell sorter. As determined
by FACS analysis, the purity of the CD8+ was 98%.
2.8.  Immunological T-cell assays
Ex vivo ELISPOT (IFN-) or in vivo cytotoxicity assays were per-
formed exactly as described previously [13,25]. Brieﬂy, the in vivo
cytotoxicity assays, C57BL/6 splenocytes were divided into two
populations and labeled with the ﬂuorogenic dye carboxyﬂuores-
cein diacetate succinimidyl diester (CFSE Molecular Probes, Eugene,
Oregon, USA) at a ﬁnal concentration of 10 M (CFSEhigh) or 1 M
(CFSElow). CFSEhigh cells were pulsed for 40 min at 37 ◦C with 1 M
of the H-2 Kb ASP-2 peptide (VNHRFTLV) or TsKb-20. CFSElow cells
remained unpulsed. Subsequently, CFSEhigh cells were washed and
mixed with equal numbers of CFSElow cells before injecting intra-
venously (i.v.) 30 ×106 total cells per mouse. Recipient animals
were mice that had been infected or not with T. cruzi. Spleen cells or
2884 M.R. Dominguez et al. / Vaccine 30 (2012) 2882– 2891
Fig. 1. Kinetics of the speciﬁc CD8+ T-cell-mediated immune responses in mice infected with T. cruzi
C57BL/6  mice were challenged s.c. with 104 blood-borne trypomastigotes of the Y strain of T. cruzi. At the indicated days, IFN--producing cells were estimated ex vivo by
using the ELISPOT assay in the presence of peptides VNHRFTLV (Panel A) or TsKb-20 (Panel B). The in vivo cytotoxic activities were estimated against target cells coated with
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ells. In that case, we  pooled cells from 4 mice for analysis. Asterisks denote the fre
P  < 0.05).
ymph node cells of recipient mice were collected 20 h after trans-
er, ﬁxed with 3.7% paraformaldehyde and analyzed by FACS as
escribed above. The percentage of speciﬁc lysis was  determined
sing the formula:
 − %CFSEhigh infected/%CFSElow infected
%CFSEhigh naive/%CFSElow naive
×  100%
The surface mobilization of CD107a and the intracellular expres-
ion of cytokines (IFN- and TNF-) were evaluated after in vitro
ulture of splenocytes in the presence or absence of an antigenic
timulus. Cells were washed 3 times in plain RPMI and re-
uspended in cell culture medium containing RPMI 1640 medium
pH 7.4), supplemented with 10 mM Hepes, 0.2% sodium bicarbon-
te, 59 mg/L penicillin, 133 mg/L streptomycin, and 10% Hyclone
etal bovine sera (Hyclone, Logan, Utah). The viability of cells was
valuated using 0.2% Trypan Blue exclusion dye to discriminate
etween live and dead cells. The cell concentration was adjusted
o 5 × 106 cells/mL in a cell culture medium containing anti-CD28
2 g/mL, BD Pharmingen), brefeldin A (10 g/mL, BD Pharmin-
en), monensin (5 g/mL, Sigma, St. Louis, MO), and FITC-labeled
nti-CD107a (Clone 1D4B, 2 g/mL, BD Pharmingen). In half of the
ultures, VNHRFTLV peptide was added at a ﬁnal concentration of
0 M.  Cells were cultivated in V-bottom 96-well plates (Corning)the values of 4 mice ± SD per group, except for the in vivo cytotoxic activity of LN
y of SFCs in the spleen of infected mice were signiﬁcantly higher than the LN cells
in  a ﬁnal volume of 200 L in duplicates, at 37 ◦C in a humid envi-
ronment containing 5% CO2. After no more than 12 h incubation,
cells were harvested and stained for surface markers with Per-CP
or PE-labeled anti-CD8 on ice for 20 min. To detect IFN-, or TNF-
 by intracellular staining (ICS), cells were then washed twice in
buffer containing PBS, 0.5% BSA, and 2 mM  EDTA and then ﬁxed and
permeabilized for 20 min  on ice with 100 L Cytoﬁx/Cytoperm (BD
Pharmingen). After washing twice with 250 L permwash buffer
(BD Pharmingen), the cells were stained to detect intracellular
markers using APC or PE-labeled anti-IFN- (clone XMG1.2) and PE-
labeled anti-TNF- (clone MP6-XT22). Finally, cells were washed
twice and ﬁxed in 1% PBS-paraformaldehyde. At least 300,000
events were acquired on a BD FACSCanto II ﬂow cytometer and
then analyzed with FlowJo (Tree Star, Ashland, OR).
2.9.  Statistical analysis
Values  are expressed as means ± SD. These values were com-(http://faculty.vassar.edu/lowry/VassarStats.html). The Logrank
test was used to compare mouse survival rates after challenge with
T. cruzi (http://bioinf.wehi.edu.au/software/russell/logrank/). The
differences were considered signiﬁcant when the P value was  <0.05.
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Fig. 2. CD11c+ cells are required for the CD8 T-cell immune responses of mice
infected  with T. cruzi.
WT  or CD11c-DTR mice were infected s.c. with 104 T. cruzi blood parasites. 48 h
before and on the day of challenge, WT and CD11c-DTR mice were treated i.p. with
50 ng of DT. One week later, IFN--producing spleen cells were estimated ex vivo by
ELISPOT in the presence of peptides VNHRFTLV or TsKb-20. Results are expressed as
means ± SD of 4 mice per group and are representative of experiments performed at
twice with similar results. Asterisks denote that the number of spots forming cells
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20, respectively (Fig. 7A).SFC) from infect WT  mice were signiﬁcantly higher when compared to naïve or
nfected CD11c-DTR mice (P < 0.01, one-way ANOVA).
. Results
During experimental infection of H-2b inbred mouse strains
ith parasites of the Y strain of T. cruzi, epitopes VNHRFTLV and
sKb-20 (ANYKFTLV) are recognized by H-2Kb-restricted CD8+
ytotoxic T cells. In previous studies we have described that the
rst is the immunodominant epitope leading to a higher immune
esponse and the second a sub-dominant epitope [10,12,13]. After
.c. challenge with infective trypomastigote forms of the para-
ite, detailed analyses of the kinetics of peptide-speciﬁc immune
esponses were determined ex vivo by ELISPOT and in vivo by cyto-
oxicity assays. At the indicated time points, spleen or LN cells were
ncubated in vitro with medium (control) or peptides (VNHRFTLV
r TsKb-20). The number of peptide-speciﬁc IFN- secreting cells
as determined by ELISPOT assay (13). Alternatively, at the indi-
ated time points, target cells were labeled with CFSE and coated
ith peptides VNHRFTLV or TsKb-20 as described in Section 2.
hese cells were transferred to infected or naïve mice. Twenty hours
ater, spleen or LN cells were collected and the in vivo cytotoxicity
stimated.
The results showed that the effector peptide-speciﬁc immune
ells developed at a similar rate in both the draining LN and the
pleen (Fig. 1A–D). The main transition occurred from days 4 to12
n both organs, for both peptides.
To determine the role of CD11c+ cells during the expan-
ion/maturation phase of the adaptive immune response, we used
ransgenic mice expressing the DTR under control of the CD11c
romoter. When infected mice were subjected to diphtheria toxin
DT), the peptide-speciﬁc immune response in their spleen 12 days
fter infection was severely compromised, as measured using the
LISPOT assay (Fig. 2). These results strongly suggest that CD11c+
ells are important for priming of peptide-speciﬁc cells following
. cruzi infection.
To  further evaluate the subpopulation of CD11c+ cells that could
otentially be involved in the priming of the peptide-speciﬁc Te 30 (2012) 2882– 2891 2885
cells, we stained LN and spleen cells with antibodies to CD11c and
PDCA-1 and the activation markers CD40, CD40L, CD80, and CD86
at different times after challenge. As depicted in Fig. 3A, a clear
upregulated pattern of expression of CD40, CD80 and CD86, but not
CD40L, can be seen on the surface of CD11c+PDCA-1+ cells obtained
from the LN. In contrast, we  detect only the upregulation of CD40
on CD11c+PDCA-1+ splenocytes at day 10 after infection (Fig. 3B).
In addition, we  also stained LN and spleen cells for CD11c
expression in conjuction with CD8 in addition to the activation
markers CD40, CD40L, and CD86 at different times after infection.
A limited pattern of upregulation of expression of CD86 can be seen
on the surface of CD11c+CD8+ cells collected from the LN or spleen
on days 3–7 following infection (Fig. 4A and B).
Similar analyses were also conducted for CD11C+CD8a− cells
collected from the spleen and LN, but we  did not detect an upregu-
lation of expression of the activation markers CD40, CD40L, CD80,
or CD86 at any time point from 3 to 30 days in the spleen or LN
(data not shown).
To  determine whether indeed CD11c+PDCA-1+ cells could
present antigen for speciﬁc CD8 lymphocytes, we  puriﬁed
CD11c+PDCA-1+. After sorting the cells from naïve or 5-day infected
LN cells, we  obtained cells that were 95.3 and 83% pure as deter-
mined by the PDCA-1 marker (Fig. 5A and B, respectively). For
some unknown reason, during the puriﬁcation process, some cells
become negative for the marker for CD11c marker but still retained
the PDCA-1 marker. The PDCA-1+ cells obtained from mice that
were infected expressed signiﬁcantly higher amounts of MHC-II-
IAb and CD80 (Fig. 5C and D, respectively). PDCA-1+ cells were
used to stimulate puriﬁed CD8+ splenic cells obtained from T.
cruzi infected mice. As shown in Fig. 5E, IFN- producing cells
were detected only when CD8+ were incubated with PDCA-1+ cells
obtained from infected mice.
The fact that CD11c+ cells from the spleen exhibit a limited acti-
vation phenotype suggested that perhaps most of the speciﬁc T cells
found in the spleen might not be primed there. If this assumption is
correct, the re-circulation of T cells could account for the CD8+ T-cell
mediated functions detected in this organ. To test whether lym-
phocyte re-circulation was responsible for the immune response
observed in the spleen, we  treated infected mice with FTY720. This
immunosupressive drug inhibits S1P1 signalling, thus efﬁciently
blocking re-circulation of naïve and activated T cells from the LNs
into peripheral tissues, thereby preventing development peripheral
T-cell responses [27–29].
Mice  were infected with T. cruzi parasites and FTY720 or dilu-
ent were administered on the same day of challenge and every 2
days thereafter as described in Section 2. Two  weeks later, the fre-
quency of IFN--producing cells were estimated ex vivo by using
ELISPOT assay in the presence of peptides VNHRFTLV or TsKb-20.
Alternatively, splenocytes were cultured in the presence or absence
of peptides VNHRFTLV or TsKb-20 and the expression of surface
CD107a, IFN- and TNF- by ICS.
In infected mice, administration of FTY720 resulted in 2.52-
or 3.05-fold increases in the frequency of IFN--secreting cells
from the LNs speciﬁc for VNHRFTLV or TsKb-20, respectively, as
detected using the ELISPOT assay (Fig. 6). In contrast, this increase
in the frequency IFN--secreting peptide-speciﬁc cells in the LN
was accompanied by a signiﬁcant decrease of immune responses
of splenic lymphocytes. Immune responses were initially deter-
mined by the frequency of IFN--producing cells as measured by
the ELISPOT assay (Fig. 7A). The frequency of IFN--producing cells
found in the spleen after FTY720 administration was  reduced by
74.55% or 100% upon stimulation with peptides VNHRFTLV or TsKb-Subsequently, we estimated the immune response by the detec-
tion of peptide-speciﬁc CD8+ cells that mobilized CD107a to their
surface and expressed IFN- and TNF- upon exposure to the
2886 M.R. Dominguez et al. / Vaccine 30 (2012) 2882– 2891
Fig. 3. Expression of activation markers on CD11c+ and PDCA-1+ DCs from the LNs or spleens from infected mice
WT C57BL/6 mice were infected s.c. with 104 T. cruzi blood parasites. At the indicated days after infection, LN (panel A) or splenic (Panel B) cells were collected and co-stained
f
T llecte
p
I
u
r
C
c
w
t
a
o
i
(
c
i
d
tor the expression of CD11c, PDCA-1, and the indicated marker.
he  expression of the different activation markers were compared between cells co
eptides in vitro. The frequency of CD8+ cells that were CD107a+,
FN-+ or TNF-+ was reduced by 74.61% or 84.15% after stim-
lation with VNHRFTLV or TsKb-20, respectively (Fig. 7B). The
eduction substantially affected all the different subpopulations of
D8+ cells (Fig. 7C). The proportions of each population did not
hange signiﬁcantly in the cells collected from infected mice that
ere administered or not with FTY720 (Fig. 7D).
To evaluate the inﬂuence of restricting T-cell re-circulation on
he outcome of infection, we also monitored the parasitemia levels
nd survival of mice that were and were not subjected to FTY720
ver the course of infection. We  found that drug exposure resulted
n increased parasitemia and accelerated mortality of infected mice
Fig. 8A and B, respectively). Therefore, we concluded that lympho-
yte re-circulation is indeed important for the acquired protective
mmune response in this mouse model of acute infection.
We  then sought to test the same hypothesis by applying a
istinctly different approach. In this case, we used highly suscep-
ible A/Sn mice that were genetically vaccinated by priming withd from infected (blue lines) and naïve (red lines) mice.
plasmid  pIgSPCl.9 followed by a booster immunization with AdASP-
2. We  previously showed that this heterologous prime-boost
regimen reproducibly conferred protective immunity against a
lethal challenge with T. cruzi [25]. Immunity was mediated by CD8+
T cells as depletion of these T cells renders these mice completely
susceptible to infection. These CD8+ T cells are speciﬁc for the ASP-
2 H-Kk restricted epitopes TEWETGQI, PETLGHEI or YEIVAGYI [31].
Prior to challenge, these mice exhibit a strong immune response to
all three epitopes [31].
Following  infection (s.c.), some of these vaccinated mice were
subjected to FTY720. We  then monitored the parasitemia levels and
survival. We  observed that drug exposure caused an increase in the
parasitemia levels and accelerated the mortality of vaccinated mice
(Fig. 9A and B, respectively). This observation indicates that vac-
cinated mice still require lymphocyte re-circulation to mount an
effective immune response on subsequent challenge. This ﬁnding
further corroborated our initial conclusions regarding the impor-
tance of re-circulation activity, even for the vaccine-supported
M.R. Dominguez et al. / Vaccine 30 (2012) 2882– 2891 2887
Fig. 4. Expression of activation markers on CD11c+ and CD8-+ DCs from the LNs or spleens of infected mice
WT  C57BL/6 mice were infected s.c. with 104 T. cruzi blood parasites. At the indicated days after infection, LN (panel A) or splenic (Panel B) cells were collected and co-stained
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rotective immune response, as seen in this second mouse model
f acute infection.
.  Discussion
The CD8+ T-cell immune response elicited by T. cruzi infection in
ost inbred mouse strains can control multiplication of this intra-
ellular pathogen and preclude acute-phase pathologies such as
eath [1,10–17]. The time at which acquired immunity develops is
ighly dependent on the parasite load [12,32]. In our model, with
he Y strain of T. cruzi, we observed that the CD8+ T-cell immune
esponse is only triggered at the time of the peak parasitemia
10,12]. Because the number of circulating parasites at this time
s high, antigen presentation could occur in the draining LN or the
pleen. However, the results of our experiments that involved the
se of the immunosupressive drug FTY720, in combination with
he identiﬁcation of activated CD11c+ cells, found mostly in the LN,
learly demonstrated that the LNs draining the parasite entrance
re where the speciﬁc CD8+ T cells are primed. Then, they exit the LN
nd reach the spleen. Our results are similar to those of experimen-
al vaccination studies with radiation-attenuated malaria parasites infected (blue lines) and naïve (red lines) mice.
[33].  In this case, the CD8+ T-cell response originates in the LN
draining site at the site of parasite entrance in the skin, and then
these cells migrate to other peripheral organs. Similar to our results,
exposure to FTY720 led to accumulation of speciﬁc T cells in the
draining LN and a ∼85% reduction of the speciﬁc CD8+ T cells in the
spleen [33]. Together, these results provide compelling evidence
that the priming of CD8+ T cells can take place in the local lymphoid
tissue during protozoan infection/vaccination and that a rapid re-
circulation to the spleen is likely to occur. As in our case, the authors
conclude that this rapid re-circulation during infection was critical
for protective immunity mediated by malaria-speciﬁc CD8+ T cells
[33].
Both studies used parasites that infect mice (T. cruzi or Plas-
modium yoelii). Nevertheless, it is important to highlight that
only T. cruzi infects humans. Also, the studies of malaria used
radiation-attenuated parasites as vaccine because they do not
cause infection. Therefore, it is unknown whether the same
occurs during acquired immunity to experimental infection as
in our case. These observations with T. cruzi and malaria para-
sites stand in contrast to other pathogens. Several studies describe
re-circulation mediated by S1P1 is not critical for the protec-
tive immune responses to certain viral, bacterial and protozoan
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Fig. 5. PDCA-1+ cells puriﬁed from infected mice present antigen to speciﬁc CD8+
cells.
PDCA-1+ cells were sorted from LN cells from mice infected 5 days earlier s.c. with T.
cruzi parasites as described in Section 2. As controls, we used PDCA-1+ cells isolated
from  LN of naïve mice.
(A  and B) Sorted cells from naïve or infected mice were stained with antibodies to
CD11c and PDCA-1. Numbers represent the frequency of cells in each gate.
(C and D) PDCA-1+ cells were stained with antibodies to IAb or CD80.
(E)  Puriﬁed PDCA-1+ cells from naïve or infected mice were used in quadrupli-
cate  cultures to stimulate speciﬁc CD8+ cells. Asterisk denotes the that number
of  SFCs of CD8+ cells stimulated with PDCA-1+ cells puriﬁed from infected mice
w
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Fig. 6. Administration of FTY720 increases the number of peptide-speciﬁc cells in
the LN of mice infected with T. cruzi.
C57BL/6 mice were infected s.c. with 105 T. cruzi blood-borne parasites. Mice were
administered on the same day of challenge and every 2 days thereafter 20 g of
FTY720 or diluent i.p. Two weeks later, the frequency of IFN--producing cells were
estimated ex vivo by using ELISPOT assay in the presence of peptides VNHRFTLV
or  TsKb-20. The results are presented as means ± SD of 4 mice per group and are
representative of experiments performed at least twice with similar results. Aster-
isks denote the number of SFCs from infected mice given FTY720 were signiﬁcantlyere  signiﬁcantly higher the one stimulated with PDCA-1+ cells from naïve animals
P  < 0.01).
nfections [34–36]. The precise reasons for these divergent
esponses are not clear but probably reﬂect differences in the prim-
ng sites as well as, the immunopathologies caused by the different
nfectious agents.
In  addition to the role of S1P1-dependent circulation during
rotective immunity acquired during T. cruzi infection, we  alsohigher  than infected mice treated with the diluent only (P < 0.01).
observed that previously vaccinated mice became more susceptible
to infection when subjected to FTY720 exposure. For vaccination,
we used a heterologous prime-boost regimen consisting of an ini-
tial immunization with plasmid DNA and a booster immunization
with a replication-defective recombinant human adenovirus type
5 (HuAd5), both encoding the asp-2 gene. Immunity elicited by this
vaccination protocol is long lived and mediated by Th1 CD4+ as well
as CD8+ Tc1 cells [25,31,37].
The heterologous prime-boosting regimen of vaccination using
plasmid DNA and replication-defective recombinant HuAd5 pro-
vides protective immunity in some other important pre-clinical
experimental models such as SIV, malaria, Ebola, and Marburg
viruses [38–45]. Based on these pre-clinical experimental mod-
els, human trials have been initiated [46–49]. Our observation that
S1P1 is important for protective activity of T cells in previously vac-
cinated animals is completely new and should be studied further
in these experimental models.
Although we  measured only CD8 T-cell mediated immune
responses only, it is highly possible that the same pattern would
happen to speciﬁc CD4+ T cells. This T-cell sub-population is very
important for protective immunity during to T. cruzi infection
[25]. The absence of re-circulation of both types of lympho-
cytes probably account for the sub-optimal protective immunity
observed after administration of FTY720. Possibly, both cells pro-
mote the processes required for parasite elimination on the
tissue.
The fact that FTY720 interfere with S1P1 activation makes it
theoretically capable of act on other cells types that express this
receptor. However, the effect on other cell types is poorly known
at present. It has been previously described that FTY720 admin-
istration may  increase or reduce the activity of regulatory T cells
[50,51]. A recent study indicated that this drug act on astrocytes
S1P1 to reduce experimental allergic encephalomyelitis clinical
scores [52]. Whether these or other cell types play a role in our
system is currently unknown.
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Fig. 7. Administration of FTY720 reduces the number of peptide-speciﬁc cells in the
spleen of mice infected with T. cruzi
C57BL/6 mice were infected s.c. with 104 T. cruzi blood-borne parasites. Mice were
administered on the same day of challenge and every 2 days thereafter 20 g of
FTY720 or diluent i.p. Two weeks later, the frequency of IFN--producing cells were
estimated ex vivo by using ELISPOT assay in the presence of peptides VNHRFTLV or
TsKb-20 (Panels A and B).
Alternatively, splenocytes from these mice were cultured in the presence of anti-
CD107a and anti-CD28, with or without the peptides VNHRFTLV or TsKb-20. After
12 h, the cells were stained to detect CD8, IFN-, and TNF- (Panels C and D). The
results  are presented as means ± SD of 4 mice per group and are representative of
experiments performed at least twice with similar results. Asterisks denote that the
n
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Fig. 8. Administration of FTY720 increases susceptibility to T. cruzi infection
C57BL/6  mice were infected s.c. with 105 T. cruzi blood parasites. Mice were treated
on  the same day of challenge and every 2 days thereafter with 20 g of FTY720
i.p.  or diluent only. (A) Parasitemia levels for each mouse group is presented as the
mean ± SD (n = 6). Asterisks denote that mice from groups injected with diluent only
exhibited signiﬁcantly lower parasitemia (P < 0.01) than animals receiving FTY720.
(B) Kaplan–Meier survival curves for the mouse groups treated as described above
(n = 6). Mice from groups injected with diluent only survived longer than animals
receiving  FTY720 (P < 0.01, Logrank test). No animals died after the 30th day until
the termination of the experiment. The results are representative of 2 independent
experiments.umber of SFCs from infected mice receiving FTY720 were signiﬁcantly lower than
he infected mice treated with the diluent alone (P < 0.01).A current limitation of this experimental model for T. cruzi infec-
ion is the lack of information on where CD8+ T cells encounter
nd eliminate parasite-infected cells; this is an aspect that may
e critical to fully understand immune responses. Consideringthat T. cruzi can infect many cell types and cause systemic
infection, it is plausible that many tissues may serve as sites
of infection and for parasite/T-cell encounters. Supporting this
hypothesis, we observed that vaccinated animals were resistant
to T. cruzi challenge by different routes of infection (i.p. and s.c.
[25,37]).
The ﬁnding that the administration of FTY720 signiﬁcantly
reduces protective immunity against T. cruzi infection and impairs
the protective immunity afforded by vaccination may  also have
clinical implications for the use of this immunosuppressive drug.
Certainly, its use in regions where Chagas disease is endemic
should be done with caution considering the potential increase in
susceptibility of treated individuals. Finally, treatment of organ-
transplanted patients with FTY720 may  interfere with immunity
elicited by previous vaccination.
In  conclusion, our study provides useful information on the
importance of S1P1 for resistance against experimental infection
with human protozoan parasites.
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Fig. 9. Administration of FTY720 increases susceptibility to T. cruzi infection in pre-
viously vaccinated A/Sn mice
A/Sn mice were primed i.m. with 100 g of plasmids, pcDNA3 or pIgSPCl.9. Three
weeks  later, these mice were boosted i.m. with 2 × 108 pfu Ad-gal or AdASP-2.
All  mice were challenged s.c. with 150 bloodstream trypomastigotes. Half of the
vaccinated mice received 20 g of FTY720 every other day, and the other half
received  diluent only. (A) Parasitemia levels for each mouse group is presented
as  the mean ± SD (n = 5). Asterisks denote that mice from groups immunized with
pIgSPCl.9/AdASP-2 and who received diluent only had signiﬁcantly lower para-
sitemia than other mouse groups (P < 0.01). (B) Kaplan–Meier survival curves for the
mouse groups immunized and challenged as described above (n = 10). Mice immu-
nized with pIgSPCl.9/AdASP-2 and receiving diluent only survived signiﬁcantly
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P < 0.01). The results shown are combined from 2 experiments. No animals died
fter the 50th day of challenge.
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